Evidence map›Paper›PMID 33783658›Full record

ReviewInternational journal of clinical oncology2022

Aging, cancer, and antitumor immunity.

Hideki Ikeda, Yosuke Togashi

Abstract readReview
PubMed Publisher
In one paragraph

Review in International journal of clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Observational
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Hideki IkedaChiba Cancer Center, Research Institute, 666-2, Nitona-cho, Chuo-ku, Chiba, 260-8717, Japan.
Yosuke TogashiChiba Cancer Center, Research Institute, 666-2, Nitona-cho, Chuo-ku, Chiba, 260-8717, Japan. ytogashi1584@gmail.com.ORCID http://orcid.org/0000-0001-9910-0164

Funding

Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan B grant no. 20H03694Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan Challenging Exploratory Research grant no. 19K22574The Practical Research for Innovative Cancer Control from Japan Agency for Medical Research and Development (AMED) 19ck0106521h0001The Project for Cancer Research and Therapeutic Evolution from Japan Agency for Medical Research and Development (AMED) 18cm0106340h0001
6 · The paper itself

Abstract

Aging leads to numerous changes that affect many components of the immune system, called "immunosenescence". Indeed, elderly individuals exhibit dysregulated immune responses against pathogens, poor responses to vaccination, and increased susceptibility to many diseases including cancer, autoimmune disorders, and other chronic inflammatory diseases. Despite progressed understanding of immunosenescence, its detailed mechanisms are still not fully understood. With advances in medicine, the population of older cancer patients is expected to rapidly increase in the coming years. Cancer immunotherapies, including immune checkpoint inhibitors (ICIs), have been shown to be effective for multiple cancer types, whereas to date, few specific data for elderly individuals have been published. Some systemic reviews have demonstrated that ICIs exhibit similar efficacy in older cancer patients, but they seem to be less effective in very old patients. In addition, toxicities might be more frequently observed in such patients. Here, we provide a summary to better understand immunosenescence and an overview of its relationship with cancer and antitumor immunity, including the efficacy and toxicity of ICIs.

Indexed as

ImmunosenescenceNeoplasmsAgedAgingHumansImmunotherapyVaccinationAgingAntitumor immunityImmune checkpoint inhibitorImmunosenescence

Identifiers

PMID33783658

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.